Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laif 900 for Relapse Prevention in Moderate Depression
NCT04315597Phase 3Completed
- Sponsor
- Bayer
- Start
- Mar 2009
- Primary completion
- Nov 2011
- Modality
- HM (Herbal Medicine)
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Laif 900 with Placebo (2 arms). Primary endpoint: Relapse rate at 24 weeks. Started Mar 2009; status: completed.
02
Drugs
Laif
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04315597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04315597.